



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/760,002	01/16/2004	David Solow-Cordero	061030-0055	8662

24341 7590 04/25/2006

MORGAN, LEWIS & BOCKIUS, LLP.
2 PALO ALTO SQUARE
3000 EL CAMINO REAL
PALO ALTO, CA 94306

EXAMINER

KWON, BRIAN YONG S

ART UNIT	PAPER NUMBER
----------	--------------

1614

DATE MAILED: 04/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 3-27 and 29-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with tetrazole compounds when X, Y, Z is N, classified in class 514, subclass 381.
 - II. Claims 1, 3-27 and 29-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with triazole compounds when X and Z is N; Y is C, classified in class 514, subclass 383.
 - III. Claims 1, 3-27 and 29-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with pyrazole compounds when X, Y, Z is C, classified in class 514, subclass 406.
 - IV. Claims 1 and 3-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with imidazole or diazole compounds when X and Z is C; Y is N, classified in class 514, subclass 396.
 - IV. Claims 1, 3-27 and 29-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with 1, 2,5 thiadiazole compounds when X is S; Y is N; Z is C, classified in class 514, subclass 362.
 - V. Claims 1, 3-27 and 29-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with oxadiazole compounds when X is O; Y is C; Z is N, classified in class 514, subclass 364.

Art Unit: 1614

VI. Claims 1-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with thiazole compounds when X is C; Y is C; Z is C, classified in class 514, subclass 372.

VII. Claims 1 and 3-32, drawn to a process of modulating an Edg-7 receptor mediated biological activity with oxazole compounds when X is O; Y is C; Z is C, classified in class 514, subclass 374.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

2. In addition, applicant is required under 35 U.S.C. 121 to elect a single disclosed species of (i) compound (e.g., compound 105) and (ii) disease condition (e.g., cancers) under the instant claims of the elected Group. Moreover, whatever specific compound and disease condition are ultimately elected, applicants are required to list all claims readable thereon. With the election of a specific exemplified compound(s) and disease(s), a generic concept will be identified by the examiner as the inventive group for examination.

For instance, each of the species of disease conditions (e.g., cancers, acute lung diseases, cardiovascular disease and surface epithelial cell injury) recited in the claims is recognized in the art to be distinctive because they would appear to seek results that differ depending on what diseases or conditions is being treated. One practicing the invention of any of the disease conditions (i.e., cancers) would not necessarily be required to practice any of the others (i.e., cardiovascular disease or lung disease).

Art Unit: 1614

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (703) 308-5377. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (571) 272-0951. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Art Unit: 1614

Brian Kwon
Patent Examiner
AU 1614

A handwritten signature in black ink, appearing to read 'B. Kwon', followed by a long horizontal line extending to the right.